|

BGB-B2033 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • BeOne Medicines1

Indications

  • Liver Disease1
  • Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer1
  • Extragonadal Yolk Sac Tumors1
  • Alpha-fetoprotein (AFP)-Producing Gastric Cancer1
  • Local Advanced Hepatocellular Carcinoma1

New York, New York1 trial

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

Memorial Sloan Kettering Cancer Center Mskcc

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.